ARTICLE | Clinical News
XTL starts Phase II
May 16, 2001 7:00 AM UTC
XTL Biopharmaceuticals (LSE:XTL) began double-blind placebo-controlled Phase II testing of its XTL-001 in combination with Zeffix lamivudine 3TC from BioChem Pharma to treat chronic hepatitis B virus ...